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Introduction
Articular cartilage lesions of the knee are common in active
and young population.1 Curl et al2 reviewed more than
30,000 patients treated with knee arthroscopy, reporting
chondral lesions in 63% of cases. Arøen et al,3 in a group of
approximately a thousand patients undergoing knee arthro-
scopy with a mean age of 35 years, found a full-thickness
cartilage lesion suitable for cartilage repair in 11% of cases.
Several studies reported Outerbridge grade III and IV lesions
in 5 to 20% of all patients undergoing knee arthroscopy, with
4 to 5% of these patients being younger than 40 years.2–4
Different techniques can be used to repair osteochondral
lesions of the knee, and these can be categorized into four
group: bone marrow stimulation procedures, osteochondral
scaffold, cell therapies, and osteochondral grafting. Debride-
ment and microfractures with bone marrow stimulation are
suitable options for lesions smaller than 2 cm2 without
subchondral bone damage.5–7 These procedures result in
fibrocartilage repair tissue; this tissue has poor biomecha-
nical properties compared with hyaline cartilage, degener-
ates faster, and is generally thinner.8–10 Autologous
mosaicplasty has the potential to restore small osteochon-
dral lesions but is not indicated in large lesions (>2.5 cm2)
due to significant donor-site morbidity and the technical
difficulties in restoring curved surfaces and uncontained
defects.11–14 Autologous chondrocytes implantation pro-
vides surface coverage with hyaline-like repair tissue, but
it is costly, entails two surgical procedures, and does not
restore associated bone defects unless bone grafting is
performed.15 Cell-free scaffolds and the use of growth factors
are promising new technologies but require additional
Keywords
► knee
► chondral lesion
► osteochondral lesion
► allograft
► osteochondral
allograft
Abstract Large osteochondral allograft (OCA) transplant has become a valid alternative to
restore articular surface in challenging articular lesions in young and active patients,
either in primary or in revision procedures. Several studies support the effectiveness
and safety of OCA, but costs and graft availability limit their use. The indications are the
treatment of symptomatic full-thickness cartilage lesions greater than 3 cm2, deep
lesions with subchondral damage, or revision procedures when a previous treatment
has failed. The goal of the transplant is to restore the articular surface with a biological
implant, allow return to daily/sports activities, relieve symptoms, and delay knee
arthroplasty. Grafts can be fresh, fresh-frozen, or cryopreserved; these different
storage procedures significantly affect cell viability, immunogenicity, and duration
of the storage. Dowel and shell technique are the twomost commonly used procedures
for OCA transplantation. While most cartilage lesions can be treated with the dowel
technique, large and/or geometrically irregular lesions should be treated with the shell
technique. OCA transplantation for the knee has demonstrated reliable mid- to long-
term results in terms of graft survival and patient satisfaction. Best results are reported:
in unipolar lesions, in patients younger than 30 years, in traumatic lesions and when the
treatment is performed within 12 months from the onset of symptoms.
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studies to confirm the initial good results in small lesions
with little damage to the subchondral bone.13 Stem cell
therapy showed promising results, but currently, clinical
and preclinical trials are trying to establish the optimal
cell type to use, the safety, and the efficacy.16
Osteochondral allograft (OCA) represents a solution for
the treatment of large and deep osteochondral lesions, in
both primary and revision procedures, with different advan-
tages: possibility of covering virtually all sizes of defects,
presence of subchondral bone, possibility of restoring com-
plex surfaces and uncontained lesions, and absence of donor-
site morbidity.17–28 The main limitations of OCA are costs
and graft availability.29
OCAs are most commonly used for femoral condyle
defects, but they can also be used in tibial plateau and
patellofemoral defects. The goals for OCA transplant are to
restore the articular surface, return to daily/sports activities,
relieve symptoms, and delay knee arthroplasty,18,20 consid-
ering that knee arthroplasty has shown inferior outcomes in
young patients.30,31
Indications
OCA is indicated for the primary management of sympto-
matic full-thickness cartilage lesions greater than 3 cm2 or
localized Outerbridge grade III or IV lesions with subchon-
dral bone damage greater than 6 to 10 mm.5,19,32–35 OCA
transplants have also proven to be a useful revision cartilage
restoration procedure after microfractures, osteochondral
autograft transplantation, or autologous chondrocyte
implantation.8,36 OCA transplantation can be used in differ-
ent scenarios such as osteonecrosis, osteochondritis disse-
cans (OCD), and degenerative or posttraumatic focal
lesions.1,23–27,37 Extreme indications include hemicondylic
and whole condylic grafting; these are suitable for young
high-demanding patients with large posttraumatic lesions
or bone reconstruction for tumor resections.1,20,23–27
Only a few studies on osteochondral tibial lesion manage-
ment are available reporting transplant of the whole tibial
plateau, and this should be considered only in case of large
and deep lesions or failed prior surgery (i.e., fracture reduc-
tionfixation or failed cartilage procedure).20 If a concomitant
meniscal deficiency is present, a combined OCA transplant
and meniscal allograft transplant (MAT) should be consid-
ered.38 Also, in patellofemoral lesions, OCAs have to be
considered only in revision surgery after failed cell-based
or cell-free techniques.20
OCA transplantation should only be considered as a
primary approach in young patients when complete patellar
or trochlear resurfacing is required.20
Absolute contraindications include early and multicom-
partmental osteoarthritis (OA), inflammatory arthropathies,
and altered bone metabolism (i.e., smokers, alcohol abusers,
and chronic steroid users).17
Bipolar OCAs are generally contraindicated because of the
poor results described in the literature.39–41 Ligamentous
instability, malalignment, and the absence of >50% of the
ipsilateral meniscus are relative contraindications that may
require concomitant surgical procedures.17
Obese patients (body mass index > 30 kg/m2) and low-
demand patients whomeet the criteria for joint replacement
should not be indicated for OCA.18
Preoperative Planning
A detailed clinical history, accurate examination, and ima-
ging must be obtained. Preoperative radiographic views
should be obtained with sizing markers to calculate the
appropriate allograft size. They include long-leg standing
anteroposterior view to assess the mechanical axis, Rosen-
berg view to assess the femorotibial joint line, and lateral,
sunrise, or Merchant views to assess the patellofemoral joint
(►Fig. 1).8 Alternatively, magnetic resonance imaging (MRI)
can be used to determine the allograft size,32 although MRI
Fig. 1 (A) Anteroposterior X-ray view of a medial femoral condyle osteochondritis dissecans with varus malalignment. (B) Coronal magnetic
resonance imaging (MRI) of the same case. (C) Postoperative anteroposterior X-ray view after opening-wedge high tibial osteotomy and medial
femoral condyle osteochondral autograft transplantations.
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can underestimate the size of the lesion up to 60%.42,43 In
addition, MRI is necessary to evaluate ligaments, menisci,
and subchondral bone.20
Computed tomography (CT) scan is useful to evaluate the
involvement of the bone around the defect or patellofemoral
maltracking/instability.20
The imaging of the affected knee is sent to the tissue bank
for correct sizing of the OCA.44
Harvesting, Processing, and Storage
The primary goal of the storage is to biologically preserve
subchondral bone and keep viable chondrocytes after trans-
plantation;18 this aspect is of paramount importance to
achieve good results with OCA.45,46
Grafts can be fresh, fresh-frozen, and cryopreserved;
these different storage procedures have different conse-
quences on cell viability, immunogenicity, and duration of
the storage itself.
A long storage time jeopardizes both biomechanical
properties of the cartilage and viability of chondrocytes.47
In fresh OCA stored at 4°C, chondrocyte viability starts to
decrease from the third week of storage, and for this reason,
the graft should be used within 28 days from harvesting (at
this time point, 70% of chondrocytes are still alive and
active).1,45,48
Cryopreserved OCAs are stored in a cryoprotectant sto-
rage medium of glycerol or dimethyl sulfoxide at –70°C in a
controlled procedure to protect cell viability, but this tech-
nique is controversial due to failure of the cryopreservant to
penetrate the deeper zones of the graft.49,50
Fresh-frozen OCAs undergo deep freezing to –80°C and
have the advantage of potential long storage time and
decreased immunogenicity; however, up to 95% of the
chondrocytes are lost with this technique.1,51,52 The low
portions of viable chondrocytes in both fresh-frozen and
cryopreserved grafts have limited their use.53
Fresh OCAs are stored in either saline solution or Ringer’s
lactate medium at 4°C. Graft storage in saline solution has
produced higher cell viability in respect to Ringer’s lactate at
14 days (91 vs. 81%) and at 28 days (83 vs. 29%).54 Recent
studies found that fresh grafts stored for 4 weeks at physio-
logical temperature (37°C) significantly improved the
amount of viable chondrocytes compared with grafts stored
at 4°C.36,55,56 Ideal implantation of fresh grafts is within the
first 28 days and notmore than 6weeks fromharvesting.57,58
Currently, small allografts are not blood-type or human
leukocyte antigen matched because of the barrier provided
by intact hyaline cartilage.20
Harvesting is performed removing the knee “en bloc” and
washing away with pulse lavage the bone marrow, which is
the main source of potential disease transmission and
immune response; the graft is then placed in an antibiotic
solution for 24 hours before storage.36 The lavage signifi-
cantly decreases the antigenic potential, but the persistence
of few cells from the bone marrow may elicit immune
responses.18 Despite the absence of matching procedures,
recipients usually have little or no evidence of graft-versus-
host disease and no humoral immune response.59–61
Surgical Techniques
Intravenous antibiotic prophylaxis is administered. General
or spinal anesthesia is performed. The patient is positioned
supine on the operating table with a tourniquet at the
proximal thigh. A standard midline straight skin incision is
performed followed by a lateral or medial parapatellar
arthrotomy. Dowel and shell techniques are the two most
commonly used.62 While most cartilage lesions can be
treated with the dowel technique, large and/or irregular
lesions should be treated with the shell technique.63
Femoral Dowel Allograft
The size of the lesion is determined by identifying healthy
cartilage walls and by using the templates/sizers usually
available in most OCA instrumentations.
After selecting the proper dowel size, a guidewire is
positioned perpendicular to the articular surface into the
center of the lesion using the sizers. The dowel and the socket
are drilled with a reamer to an ideal depth of 6 to 8 mm
without exceeding 10 mm in depth (►Fig. 2A). When the
lesion is deeper than 8 to 10 mm (i.e., in case of avascular
necrosis), the necrotic bone is debrided until healthy, bleed-
ing bone is visible, and autologous bone grafting (from the
iliac crest or proximal tibia) is used to fill the defect up to the
ideal depth of 6 to 8 mm from the articular surface. The
recipient site is then measured at 12, 3, 6, and 9 o’clock
positions.
The osteochondral donor plug is harvested from the
allograft with the use of a workstation and a coring reamer
to match the corresponding recipient site (►Fig. 2B, C). The
measurement made on the recipient site is then transferred
on the osteochondral plug, and the excessive bone is
removed. Pulsatile lavages are performed to remove residual
bonemarrow. For the correct orientation, a 12 o’clockmark is
made in both the recipient and the donor plug.
The graft is then gently (with the thumb initially and then
with a padded tamp) implanted (press-fit) into the recipient
socket64 (►Fig. 2D).
When a single plug is not enough to cover the whole
lesion, the procedure can be repeated using the “snowman
technique” or “mastercard technique” (►Fig. 2E). Usually, no
fixation is required, but bioresorbable pins or screws can be
used (►Fig. 2F). The knee is then moved through a complete
range of motion (ROM) to verify graft stability and potential
impingements.
Femoral Shell Allograft
For larger or irregular femoral condyle lesions, a shell graft-
ing technique is generally used. After identification of the
condylar lesion, a shell graft is handcrafted to minimize the
damage to the native healthy cartilage.
The recipient site should have a depth of at least 4 to
5 mm, creating a flat surface; all the necrotic or damaged
bone around the lesion should be removed.
The graft is then planned and marked with a paper
template and freehand crafted slightly oversized with
respect to the recipient area. The graft is then gradually
Joints Vol. 6 No. 1/2018
Knee Large OC Allografts Pisanu et al.44
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
downsized until a perfect fit is achieved. The transplant is
temporarily fixed with Kirschner wires (K-wires), and the
knee is moved through complete ROM, ruling out potential
impingement. Definitive fixation is performed with biore-
sorbable pins or compression screws.
Patellar Allograft
For the treatment of extensive patellar osteochondral
defects, a shell technique can be used. The recipient patella
is measured, and a bone cut is performed parallel to the
patellar and quadriceps tendons, as in patellar resurfacing
during total knee replacement. To minimize the risk of host
fractures, the resection should leave at least 12 to 15 mm of
the bone. The graft is prepared and fixed in positionwith the
previously described shell technique. Overstuffing should be
avoided in order to not put too much pressure on the graft.
Complete Extensor Mechanism Allograft
This graft is composed of the proximal tibia, the patellar
tendon, the patella, and 5 to 8 cm of the quadriceps tendon.
At the recipient site, the residual patella is carefully removed.
The midline incision is carried into the recipient quadriceps
and over the tibial tubercle. The tibial bone plug of the graft is
createdfirst, and thenamatching tibial trough is created at the
recipient site. Before creating any tibial trough, the allograft
tibial bone is prepared as planned to ensure a perfect press-fit.
The length of the bone block should be at least 6 to 8 cm. The
depth and the width of the block is approximately 1.5 to 2 cm.
The tibial graft is trimmed and proximally dovetailed, and the
recipient site is prepared accordingly to prevent proximal
migration. Many techniques have been described for tibial
tubercle fixation (i.e., screws, stainless cerclages, suture
anchors, bone sutures). When fixing allografts, usingminimal
fixation is important to obtain full integration of the bone and
avoid graft breakage. At this point, the quadriceps tendon is
fixed with nonabsorbable sutures with pants-over-the-vest
technique.65 The graft tissue usually loses tension overtime
and therefore needs to be tensioned tightly with the knee in
full extension, without testing the ROM.66
Tibial Allograft
This technique is usually indicated in tibial plateau (mostly
lateral) fracturemalunion (►Fig. 3). The tibial plateau is cut 1
to 2 cm deepwith an oscillating saw depending on the size of
the defect. The transverse cut is made perpendicular to the
long tibial axis and runs anterior to posterior to match the
slope, ensuring adequate coronal and sagittal alignment
(►Fig. 4A). The sagittal plane cut is performed to preserve
the tibial eminence and the meniscal root of the opposite
compartment. Themeniscus of the accepted compartment is
removed, preserving the meniscal wall for fixation of the
meniscal graft. Once the damagedplateau andmeniscus have
Fig. 2 Intraoperative pictures of osteochondral autograft transplantations and distal femoral opening-wedge varus osteotomy for a lateral
femoral condyle osteochondritis dissecans and valgus malalignment. (A) Creation of the recipient site. (B) Femoral condyle allograft on the
workstation. (C) Creation of the osteochondral plug. (D) Gentle impaction of the plug in the recipient site (press-fit). (E) When necessary, the
procedure can be repeated by creating a new recipient site. (F) Second plug in place.
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been removed from the joint, a step cut osteotomy is then
performed to improved graft stability.
The OCA of the tibial plateau is prepared in similar shape
and size to restore and preserve the original joint line and
meniscal attachment sites (►Fig. 4B). The allograft is tem-
porarily fixedwith K-wires, and ROM and stability are tested.
TheOCA is then fixed to the recipient proximal tibiawith two
or three 3.5-mm cancellous screws (►Fig. 4C). The meniscal
allograft is then sutured to the residual meniscal wall.
Management of Concomitant Pathology
Surgical success of the OCA requires diagnosis and manage-
ment of concomitant pathologies such as meniscal lesions,
ligament instability, and malalignment.23,38,67
Meniscal pathologies are a relative contraindication for
OCA transplant because of the fundamental role of the
meniscus in absorption and load distribution;20 repairing
peripheral lesions may restore the functional proprieties,
but, in case of meniscal deficiency, an MAT is required to
improve graft survival.23,38,67
Malalignment is evaluated during clinical examination
and with long-leg weight-bearing X-rays. If the weight-
bearing line passes in the affected compartment, corrective
osteotomy is required to unload and protect the graft.23
Generally, for the dowel technique, opening-wedge osteot-
omy is preferred. Closing-wedge osteotomy in shell or mas-
sive OCA should be preferred and performed on the bone
opposite to the OCA transplant (i.e., medial closing-wedge
distal femoral osteotomy for lateral tibial plateau OCA) to
minimize surgical procedure on the same bone.20,44,68–70
Maltracking and malalignment should also be addressed
when present in patellofemoral OCA (tibial tuberosity-tro-
chlear groove [TT-TG] distance > 20 mm).71
Rotational and translational stability is critical for the
success of all cartilage procedures, allowing normalization of
stress forces and avoiding shear forces that may increase
transplant damage over time;72 therefore, ligament recon-
struction is mandatory in case of associated knee instabil-
ity.20,72 Pearls and pitfalls in the surgical techniques are
described in ►Table 1.
Fig. 3 (A) Preoperative anteroposterior X-ray view of a lateral tibial plateau malunion with valgus malalignment. (B) Postoperative
anteroposterior X-ray view after distal femoral closing-wedge varus osteotomy and lateral tibial plateau/meniscus transplant.
Fig. 4 Intra-articular phase of the case described in Fig. 3. (A) Resection of the damaged lateral tibial plateau. (B) Lateral tibial plateau þ lateral
meniscus transplant (not the step-cut osteotomy to improve graft stability). (C) Fixation of the graft with two 3.5-mm cortical screws.
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Postoperative Rehabilitation
Postoperative rehabilitation starts immediately after sur-
gery. Several authors recommend the use of a knee brace,
but no consensus exists on its use.24,73
Early progressive nonweight-bearing ROM is encouraged
to promote healing process and graft vascularization. Non-
weight-bearing is necessary until standard X-rays demon-
strate graft incorporation; this ranges from 6 to 12 weeks
according to graft size.18,36 Patients treated for patellofe-
moral joint lesions can weight-bear as tolerated with the
knee brace locked in full extension.73 Return to sport is
usually 1 year after surgery, when full ROM, complete sta-
bility, no effusion, and optimal dynamic quadriceps strength
are achieved.74
In case of complete extensor mechanism allograft, a full-
extension knee brace is maintained for 8 weeks, avoiding full
weight-bearing. At 8 weeks, 30-degree active flexion is
allowed in a hinged knee brace, and patients can gradually
start weight-bearing. At 12 weeks, flexion is increased to
90 degrees; full flexion is gradually achieved at 6 months
from index surgery.
In case of concomitant surgical procedures (limb realign-
ment, ligamentous reconstructions, and/or meniscal surgery)
weigh-bearing and ROM restriction could be modified
accordingly.
Complications
Larger grafts are at a higher risk of collapse and fragmenta-
tion,33 which are the main causes of failure with a rate of
approximately 25% at 12.3 years of follow-up.21 In a recent
study, Tírico et al reported that the size of the lesion does not
influence the outcomes of OCA for isolated femoral defects.75
Onset of pain, joint effusion, and mechanical symptoms
are signs of graft failure due to subchondral collapse or
nonunion. Although the integration of the allograft at the
cartilage-to-cartilage interface is usually not complete, OCAs
fail when integration does not occur at the bone-to-bone
interface. Radiographs may show sclerosis, narrowing or
obliteration of the joint space, osteophytes, and subchondral
cyst formation.40 Patients who are 30 years or older at the
time of surgery have 3.5 times higher risk of allograft failure
compared with younger patients. Similarly, two or more
previous surgeries on the affected knee increase the risk of
grafts failure by 2.5 times.27
Allograft subsidence may be a milder complication caus-
ing persistent slight pain due to a low-grade chronic inflam-
matory reaction to the graft.17 Immunological reactions
could be the main cause of failure in large OCA with asso-
ciated soft tissue transplant, as in bipolar OCA of the knee.
Progressive OA and instabilitymake these specific knee OCAs
unsuitable for the treatment of posttraumatic end-stage
OA.76 The treatment options for these cases include observa-
tional approach, removal of the graft, allograft revision, or
knee arthroplasty (partial or total). The overall reoperation
rate is approximately 35%: 68% of the patients are treated
with total knee arthroplasty (TKA), 4% with unicompart-
mental knee arthroplasty, and 28% with graft removal, new
fixation, or revision.20
Infection is a serious complication and has to be carefully
ruled out as the first step in failed OCA. This is performed
with clinical examination, blood tests for inflammation
(C-reactive protein, erythrocyte sedimentation rate, white
blood cells), and joint aspiration when needed. Deep and
superficial infections have to be differentiated because of
the different treatments required. Irrigation, surgical deb-
ridement, or graft removal is necessary in case of deep
infection.
The risk of disease transmission is rare due to the strict
donor screening protocols. The estimated risk of viral trans-
mission due to donor viremia at time of donation is 1/63,000
for hepatitis B virus, 1/103,000 for hepatitis C virus,
1/493,000 for human immunodeficiency virus (HIV), and
1/129,000 for human T-lymphotropic virus.77 The estimated
risk of disease transmission with allograft tissue transplan-
tations is low; Buck et al78 reported a risk of 1/1.6 million.
Only one case of HIV transmission was reported, and it was
before the introduction of standard screenings in 1985.79,80
Table 1 Pearls and pitfalls in the surgical technique
Pearls Pitfalls
Copiously irrigate cutting surfaces with saline solution while
using reamer or saw to avoid edges heat necrosis
Delay the management of concomitant pathologies
Use a manual rasp to fine tune the graft size Leave pathological tissue in the recipient site
Copiously irrigate the graft before the transplant to remove
the last remaining bone marrow cells
Use OCA plugs > 10 mm of thickness
Find landmarks on both the graft and the recipient site to
harvest the corresponding area
Uncorrected orientation of the graft into the recipient site
The extensor mechanism allograft must be tensioned tightly
with the knee in full extension, avoiding ROM maneuvers at
the end
Forcing the Implant of the graft and causing a damage to the
cartilage superficial layer
Insert autologous bone graft in the recipient socket to
improve graft stability in case of unperfected graft fitting or
deep (>10 mm) lesions
Press-fit fixation of a downsized graft
Abbreviation: OCA, osteochondral allograft.
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Literature Review
Femoral and tibial OCA results are summarized in ►Tables 2
and 3, respectively. OCA transplantation in the knee has
demonstrated reliable mid- to long-term results in terms
of graft survival and return to activity. The femoral condyle is
the most common site of OCA transplantation in the knee.
Davidson et al81 reevaluated femoral OCA transplant
with second-look arthroscopy, radiological analysis, and
biopsies. MRI and standard X-rays showed improvement of
the mean Outerbridge MRI score from 4.3 preoperatively to
0.6. Histological analysis did not show significant differences
between the graft and native cartilage. All the clinical scores
analyzed (International Knee Documentation Criteria
[IKDC], Lysholm, and 36-Item Short Form Health Survey
[SF-36]) improved significantly.
Recent studies by Krych et al,74 Nielsen et al,82 and
McCarthy et al83 showed nearly 80% of return to sport at
preinjury level. Collegiate and professional athletes were all
able to return to play. Risk factors affecting the ability to
return to sport were age older than 25 years, preoperative
duration of symptoms longer than 12 months, female sex,
and graft dimension.
McCulloch et al25 in 25 consecutive OCA transplants for
femoral condyle defects showed graft incorporation in 22
patients at a minimum 2-year follow-up. Significant
improvements were also reported in all subjective outcome
scores.
Emmerson et al84 studied 66 femoral OCDs treated with
OCA transplant, and the survivorship analysis showed 91%
survivorship at 2 years and 76% at 15 years. More than 90% of
the patients were satisfied and had pain relief.
Murphy et al12 in a series of 39 young patients showed an
OCA survivorship of 90% at 10 years. The authors reported
improvement in all outcomes assessed: IKDC, modified
MerleMerle D’Aubigné and Postel, and Knee Society function
scores. Four out of five failed grafts were successfully revised
with an additional allograft transplant.
Levy et al27 reported the largest retrospective series of
OCA transplants of the femoral condyles. In total, 123
patients were followed for at least 10 years after fresh
OCA, and the survivorship was 82%.
Raz et al13 performed 58 distal femoral OCA transplants
and reevaluated them at a mean of 21.8 years. The authors
reported excellent long-term survival rates, a reoperation
rate of 22%, and good knee function in patients with graft
survival.
Gross et al23 performed 72 femoral OCA transplants in a
prospective study with 10 years of follow-up. Survivorship
analysis showed 85% of graft survival at 10 years. One-fifth of
the grafts required revision surgery or TKA, and in 40 of the
remaining grafts, good-to-excellent results were achieved
with the Hospital for Special Surgery (HSS) score.
Ghazavi et al34 performed OCA transplants to reconstruct
posttraumatic defects (tibia, femur, and patella) inmore than
100 patientswith long-term follow-up. Of the 126 knees, 86%
were successfully reconstructed. They reported 50%of failure
rate in bipolar OCA. Survivorship analysis showed 95% graft
survival at 5 years, and 66% at 20 yearswith a postoperatively
HSS knee score increased from 66 to 83 points. Gracitelli
et al85 performed a similar study on OCA transplant to treat
posttraumatic defect. One-quarter of the OCAs is considered
failed, and the reoperation rate was 50%. Eighty percent of
the patients reported satisfactory results at amedian follow-
up of 6.6 years; the reported survivorship was 80% at 5 years
and 70% at 10 years. Wang et al86 treated 54 patients aged
> 40 years with OCA to treat femoral and patella osteochon-
dral defects. They reported higher failure and reoperation
rates compared with other series of younger patients and a
4-year survivorship rate of 73%.
Gross et al23 treated 67 knees with tibial posttraumatic
OA due to tibial plateau fractures and reported graft survival
of 95% at 5 years and 46% at 20 years. About one-third of them
required knee arthroplasty after graft failure at approxi-
mately 10 years after OCA transplant. Drexler et al69 per-
formed 27 combined procedure of OCA transplant and distal
femoral osteotomy for tibial posttraumatic OA with a long-
term follow-up. They reported approximately 90% of good-
to-excellent score at 2 years and approximately 90% of graft
survival at 10-year follow-up. However, survivorship
declined significantly over time to 23.8% at 20 years. They
reported a similar decline in the Knee Society function score
and the Knee Society score. Getgood et al38 in a recent
retrospective series of OCA and concomitant MAT reported
a high total reoperation rate, but 78% of patients were
satisfied or extremely satisfied at the final follow-up. Similar
results were reported by Harris et al68 in patients treated
with combined corrective osteotomy, MAT, and cartilage
procedures (12 OCAs). Frank et al87 compared, with a
mean follow-up of 5 years, patients who underwent femoral
OCA and associated MAT with patients without associated
MAT. Graft survivorshipwas 86% at 5 years. They did not find
any significant difference between the groups regarding
patient-reported clinical outcomes score, failure rates, reo-
peration rate, and time to reoperation.
Colangeli et al88 compared OCA transplants and knee
modular megaprosthesis for the reconstruction of the knee
after proximal tibia bone tumors in young patients at amean
follow-up of 37 and 63 months, respectively. They found a
lower incidence of knee extension lag, a greater quadriceps
strength, and a higher rate of normal knee pattern during
gait with OCA. In their series, OCA transplant had better
outcomes compared with knee megaprosthesis. Muscolo
et al89 reviewed 58 OCA transplants after proximal tibia
resection due to bone tumors, and a survival analysis
revealed 65% graft survivorship at 10 years. Other series of
limb salvage procedures with OCA transplant after proximal
tibia bone tumors reported success rates from 66 to 80%.90,91
Imanishi et al92 reported four limb salvage procedures
with reconstruction of extensor mechanism using bone–
patellar tendon–bone (BPTB) allograft after sarcoma resec-
tion with satisfactory results and complete ROM in all
patients at 18- to 67-month follow-up. At 1 year after
surgery, all junctions between bone allograft and residual
bones were united. Drexler et al93 used an extensor mechan-
ism BPTB allograft to reconstruct a posttraumatic defect of
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the extensor mechanism in a young and active patient with a
failed posttraumatic partial patellectomy. At 6 months after
surgery, the union of the allograft was seen on X-rays, and
the patient returned to his previous sporting activitieswith a
full ROM. Rosenberg94 reviewed at a mean of 5-year follow-
up 50 patients treated with extensor mechanism BPTB
allograft in extensor mechanism rupture after TKA. The
author reported a high rate of complication and 19% of
failure, and only 56% of the patients had full active extension.
Despite these poor outcomes, other authors reported
encouraging results in the management of failed extensor
mechanism after TKA using BPTB allograft.95,96
Bakay et al,40 using mushroom-shaped cryopreserved
OCA, performed eight whole patellar surface replacement
with a success rate of 75% at a mean follow-up of 19 months.
During the last decade, the use of OCA in the patellofemoral
joint has notably increased. Jamali et al71 in a case series of
patellofemoralOCAreported improvement inpatient-reported
outcomes score, but one-quarter of the operated knees
required a major revision within 2 to 5 years postoperatively.
Table 2 Femoral osteochondral allograft results
Author (year) No. of cases
(mean age)
Pathology
(mean size)
Technique Follow-up Results
Davidson et al
(2007)
10 (32.6) OCD, trauma
(5.4 cm2)
Dowel 40 mo Outerbridge MRI: 4.3!0.6 IKDC:
27! 79 Lysholm score: 37! 78
SF-36: 38 ! 51
McCulloch et al
(2007)
25 (35) OCD, trauma,
osteonecrosis
(5.2 cm2)
Dowel 2.9 y Graft incorporation: 88%
Survivorship: 96% at 2 y
KOOS: 43 ! 73
SF-12: 36 ! 40
IKDC: 29 ! 58
Lysholm score: 39 ! 67 Failure
rate: 4%
Krych et al
(2012)
43 (32.9) OCD, trauma
idiopathic
(7.2 cm2)
Dowel 2.5 y Return to play: 80%; professional
athletes 100%
Survivorship: 100% at 2 y IKDC:
46 ! 79
KOOS ADL: 62 ! 82
McCarthy et al
(2017)
13 (19) N/A Dowel 5.9 y IKDC: 38 ! 63 Lysholm score:
41! 64 SF-12: 35! 44 Return to
play: 77%
Emmerson et al
(2007)
66 (28.6) OCD
(7.5 cm2)
Dowel
Shell
7.7 y Survivorship: 91% at 2 y; 76% at
15 y
D&P: 13!17
Failure rate: 15%
Levy et al
(2013)
129 (33) OCD, trauma,
osteonecrosis,
idiopathic
(8.1 cm2)
Dowel
Shell
13.5 y Survivorship: 82% at 10 y, 74% at
15 y, 66% at 20 y
KSF: 66 ! 83
D&P: 12!16 Failure rate: 24%
Murphy et al
(2014)
39 (16.4) OCD, trauma,
osteonecrosis,
idiopathic
(8.4 cm2)
Dowel
Shell
8.4 y Survivorship analysis:
90% at 10 y IKDC: 42!75
D&P: 13!17
KSF: 69!89
Failure: 12%
Raz et al (2014) 58 (28) OCD, trauma Dowel
Shell
21.8 y Survivorship: 91% at 10 y;
84% at 15 y; 69% at 20 y;
59% at 25 y Failure rate: 22%
Nielsen et al
(2017)
149 (31) OCD, trauma,
idiopathic,
osteonecrosis
Dowel
Shell
6 y Return to play: 75% IKDC:
42 ! 74 D&P: 13!17
KSF: 72 ! 91 Failure rate: 9.4%
Gross et al
(2005)
60 (42.8) OCD, trauma,
idiopathic,
osteonecrosis
Shell 11.8 y Survivorship: 95% at 5 y; 85% at
10 y; 74% at 15 y Reoperation
rate: 20%
HSS: 83
Abbreviations: ADL, Activity Daily living; D&P, D’Aubigné and Postel score; HSS, Hospital for Special Surgery score; IKDC, International Knee
Documentation Criteria; KOOS, Knee Injury and Osteoarthritis Outcome Score; KSF, Knee Society function score; MRI, magnetic resonance imaging;
N/A, not applicable; OCD, osteochondritis dissecans; SF-12, 12-Item Short Form Health Survey; SF-36, 36-Item Short Form Health Survey.
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Similar results were also reported by Torga Spak and Teitge.97
These reports were not convincing compared with cell-based
techniques, but recent reports have encouraged the use of OCA
for patellofemoral joint.98 Gracitelli et al99 in a long-term
reviewof the cohort reportedby Jamali et al71 reportedaverage
graft survival of 80% at 10 years with a substantial improve-
ment inpainandpatient satisfaction. In a case series of isolated
trochlear OCA, the survivorship analysis reported 100% at
5 years and 90% at 10 years.100
Beaver et al41 performed 19 bipolar OCAs with an average
follow-up of 68 months. Graft survivorship analysis was 60%
at 5 years and decreased to 40% at 10 years. Compared with
unipolar defects, bipolar OCAs showed a significantly lower
success rate. Giannini et al76 treated a case series of seven
kneeswith end-stageOAusing large bipolar OCA. They found
joint laxity and aseptic effusion associated with chondroly-
sis, leading to early failure in six knees. A TKAwas necessary
in these patients within 2 years of follow-up. The patient
who received the allograft to revise a knee fusion was the
only one with satisfactory results at follow-up control.
Conclusion
OCA has shown to be a safe and effective treatment for large
and/or full-thickness and/or osteochondral knee defects
using viable mature hyaline cartilage supported by an intact
subchondral bone and avoiding donor-site morbidity. In
complex or salvage procedures, OCA transplant allows for
the restoration of native bone stock. The treatment reduces
pain and improves function, especially in young and active
selected patients. In patellofemoral lesions, OCA has to be
considered only in revision surgery or when a complete
patella resurfacing is necessary. Costs, grafts availability,
systemic pathologies, and multicompartmental OA limit
the use of OCA. Management of concomitant pathologies
such as instability, malalignment, and meniscal pathologies
is crucial to the success of OCA transplant.
Mid- and long-term results are encouragingwith good-to-
excellent results and graft survival. Ideal indications are
unipolar lesions, in patients younger than 30 years old, in
traumatic etiology, and lesions treated before 12 months
from the onset of symptoms.
Future basic science research should be performed to
improve allograft processing and storage with the goal of
improving cells viability. Improvement in graft incorporation
and fixation are also necessary. Bioactive growing factors,
stem cells, three-dimensional scaffolds, and chemical mod-
ular healing agents are new technologies requiring addi-
tional prospective studies to confirm the promising initial
results.
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